학술논문
AKT mutant allele-specific activation dictates pharmacologic sensitivities
Document Type
article
Author
Tripti Shrestha Bhattarai; Tambudzai Shamu; Alexander N. Gorelick; Matthew T. Chang; Debyani Chakravarty; Elena I. Gavrila; Mark T. A. Donoghue; JianJong Gao; Swati Patel; Sizhi Paul Gao; Margaret H. Reynolds; Sarah M. Phillips; Tara Soumerai; Wassim Abida; David M. Hyman; Alison M. Schram; David B. Solit; Lillian M. Smyth; Barry S. Taylor
Source
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Subject
Language
English
ISSN
2041-1723
Abstract
How different oncogenic Akt mutants can affect the response to Akt inhibitors is currently unclear. Here, the authors analyse somatic mutations of Akt1-3 isoforms in several human cancers, investigate their oncogenic effects and therapeutic relevance in vitro and confirm some of their data in a clinical trial testing the AKT inhibitor capivasertib in patients with solid tumors harboring AKT alterations.